Furthermore, in addition to their effectiveness in improving glycemic control, SGLT-2 inhibitors have been linked to reductions in weight and blood pressure in individuals with type 2 diabetes mellitus (T2DM), whether used as a monotherapy or in combination with other antidiabetic medications [206,207]. This evidence concerns the gene SLC5A2 and diabetes mellitus.